Kling Biotherapeutics (NASDAQ: KLNG), a biotech firm that specialises in antibody-based drugs from its B-cell platform, announced on Tuesday that it has appointed Dr Stefano Gullà as Chief Scientific Officer.
Dr Gullà has more than 15 experience in biotherapeutics amd previously held key roles at Pfizer, Agenus, Flagship and RVAC, leading the development of pioneering immuno-oncology and autoimmunity therapeutics.
Michael Koslowski, Kling Bio's CEO, anticipates Dr Gullà's leadership to propel the company toward becoming a global drug discovery leader. Dr Gullà expresses excitement about scaling Kling's proven platform for cancer and infectious diseases.
Apart from his industry success, Dr Gullà founded Abcuro in 2016, raising over USD60m for cancer and autoimmune therapeutics. His academic background includes a PhD from Northeastern University and postdoctoral training at MIT.
Based in Amsterdam, Kling's 's pipeline includes KBA1412, a Phase 1 CD9 antibody for oncology. Its proprietary platforms, Kling-Select and Kling-Evolve, leverage B-cell technology for target discovery and antibody identification.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration